BioCryst Pharmaceuticals | BCRX - Pre Tax Profit


BioCryst Pharmaceuticals reported $248.02M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Chugai Pharma JPY 169.02B 8.83B Jun/2026
Daiichi Sankyo JPY -6.52B 113.25B Mar/2026
DBV Technologies USD -47.4M 14.24M Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026